Abstract：Abstract: As a novel dual Src/Abl kinase inhibitor, bosutinib (SKI-606) can significantly inhibit the prolife-ration and promote the apoptosis of esophageal cancer cells. Herein, phosphoproteomics was applied to study the effect of bosutinib on human esophageal cancer Eca-109 cells, and to explore the possible targets and functional mechanisms of bosutinib. A total of 11 335 phosphorylated peptides and 7 940 phosphorylation sites localized to 2 741 phosphorylated proteins were identified. The number of differentially phosphorylated peptide segments was 182, of which 55 were up-regulated and 127 were down-regulated. In addition to inhibiting Src and Abl, bosutinib also significantly affects the phosphorylation of JUN, ribosomal protein S6 (RPS6), CD44, SFRS protein kinase 2 (SRPK2) and other proteins. These differentially phosphorylated pro-teins are mainly involved in important biological processes such as mRNA metabolism, cytoskeletal organization, and zinc ion transport. Furthermore, transcription, translation and ribosome-associated signaling pathways were significantly enriched according to KEGG pathway analyses. These results indicated that bosutinib may inhibit the growth of esophageal cancer cells through affecting key biological processes such as mRNA metabolism, cytoskeletal organization, and zinc ion transport. JUN and RPS6 may be potential targets of bosutinib in esophageal cancer cells.
引用本文:
哈依努尔, 梁旭俊, 李茂玉, 邵美英, 付 莹, 陈 林, 陈主初. 博舒替尼抗食管癌细胞的磷酸化蛋白质组学研究[J]. 生命科学研究, 2020, 24(6): 466-475. HAYI Nu-er, LIANG Xu-jun, LI Mao-yu, SHAO Mei-ying, FU Ying, CHEN Lin, CHEN Zhu-chu. Phosphoproteomics of Inhibitory Effects of Bosutinib on Human Esophageal Cancer Cells. Life Science Research, 2020, 24(6): 466-475.
